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Summary Background Psoriasis is a common chronic and recurrent inflammatory skin disorder. Oxygen
metabolites and proteases released by activated inflammatory cells may induce oxidative and
proteolytic damage to plasma constituents and red blood cells (RBCs). RBCs have a limited
biosynthesis capacity and poor repair mechanisms.
Objectives To study RBCs as a potential cumulative marker of oxidative and proteolytic stress in
psoriasis, and as a marker of worsening of the disease.
Methods The study was performed in 70 patients with mild or severe psoriasis and in 40 control
individuals. We evaluated total and differential leucocyte count and, as markers of leucocyte
activation, plasma elastase and lactoferrin. Besides the basic RBC study (RBC count, haematocrit,
haemoglobin concentration and haematimetric indices) we evaluated antioxidant defences
(catalase, superoxide dismutase, glutathione peroxidase and selenium), osmotic fragility and
reticulocyte count; in the RBC membrane we evaluated lipid peroxidation and susceptibility to lipid
peroxidation, membrane fluidity, levels of cholesterol and phospholipids, membrane-bound
haemoglobin, band 3 profile and levels of vitamin E; serum levels of bilirubin, total plasma
antioxidant capacity, lipid profile and lipid peroxidation were also evaluated.
Results Psoriasis patients showed a rise in leucocytes, mainly neutrophils, which was associated
with a rise in elastase and lactoferrin. Patients had a reduced RBC count, antioxidant defences and
membrane fluidity, elevated membrane lipid peroxidation, membrane-bound haemoglobin, osmotic
fragility and reticulocyte count, and a different band 3 profile. Most of these modifications were
enhanced in severe psoriasis.
Conclusions In summary, our data show that the RBCs are at a lower number in psoriasis
patients, and present several changes denoting an enhanced damage and ⁄ or ageing process,
which seem to be strongly connected with neutrophil activation, oxidative stress and worsening
of psoriasis.
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Psoriasis is a chronic and recurrent inflammatory skin
disease, known as an oxidative stress condition.1,2 As
with any inflammatory disease, psoriasis often presents
a rise in leucocytes, namely in neutrophils, and a
reduction in total red blood cells (RBCs). Psoriasis
lesions that are clinically active show infiltration
of leucocytes, and several studies report high levels of
leucocyte activation products in the peripheral blood of
these patients.3,4 Activated white blood cells (WBCs)
are important sources of reactive oxygen species (ROS)
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and proteases, either of which may impose oxidative
and proteolytic changes to plasma constituents and to
circulating RBCs.5–12 Several enzymes are involved in
the RBC antioxidant defence, such as catalase (Cat),
superoxide dismutase (SOD) and glutathione peroxi-
dase (GPx), which is a selenium (Se)-dependent
enzyme. The levels of reduced glutathione (GSH) in
the cell are also important in protecting the cell from
the deleterious action of ROS. The levels of lipid-soluble
membrane vitamin E are important in the defence
against membrane lipid peroxidation.13
By diffusing across the cell membrane, oxygen
metabolites may trigger an oxidative stress within the
cells. ROS usually trigger an upregulation of the
antioxidant defences; however, an oxidative stress will
develop when the antioxidant capacity of the cell is
overwhelmed.
Presenting a limited biosynthesis capacity, the
circulating erythrocyte suffers and accumulates phys-
ical and chemical changes, which become more
pronounced with cell age, and whenever an unusual
physical or chemical stress develops.14,15 RBCs that
develop intracellular defects earlier during their life
span are removed from circulation at an earlier stage.
Several RBC studies have shown that oxidation
and ⁄ or proteolysis plays a relevant role in the
erythrocyte ageing process. Several modifications are
known to occur throughout the life span of the
circulating RBCs, namely a reduction in cell volume
and in enzymatic activity, leading to a reduction in
the metabolic activity and in the antioxidant defences
of the cell.
The removal of senescent or damaged RBCs seems to
involve the development of a neoantigen on the plasma
membrane surface, marking the cell for death.16 This
neoantigen is immunologically related to band 3, a
RBC transmembrane protein.17 The degradation of the
metabolism and of the antioxidant defences, by favour-
ing the development of oxidative stress, allows the
oxidation and linkage of haemoglobin (Hb) to band 3,
promoting its aggregation and the binding of natural
antiband 3 autoantibodies18 which, together with
complement, mediate the removal of RBCs.18,19
Several markers of oxidative stress have been studied
in psoriatic RBCs, namely the activity of antioxidant
enzymes, membrane lipid peroxidation and membrane
fluidity. Recently, changes in the domain structure of
those RBCs, namely in the portion of the most ordered
domain, were also reported as potential markers of
oxidative RBC damage, and additionally as markers for
the activity of psoriasis.20,21
Because leucocyte activation seems to be associated
with psoriasis and with worsening of the disease,4 we
wondered if the release of ROS and proteases, by
imposing oxidative and proteolytic changes to RBCs,
may lead to an accelerated RBC ageing and premature
removal. The aim of our work was to clarify the
frequent association of psoriasis with a reduction in
total RBCs, and to look for a correlation between this
reduction and worsening of the disease. For this
purpose, we studied a group of psoriasis patients with
mild or severe psoriasis and a group of controls.
We evaluated total and differential leucocyte count
and, as markers of leucocyte activation, plasma
elastase and lactoferrin. Besides the basic RBC study
[RBC count, haematocrit (Ht), Hb concentration and
haematimetric indices] we evaluated the antioxidant
defences (Cat, SOD, GPx and Se), osmotic fragility
and reticulocyte count; in the RBC membrane we
evaluated lipid peroxidation and susceptibility to lipid
peroxidation, membrane fluidity, levels of cholesterol
(Chol) and phospholipids (Phlip), membrane-bound
Hb (MBH), the band 3 profile and levels of vitamin E;
serum levels of bilirubin (as an index of RBC
removal), total plasma antioxidant capacity, plasma
lipid profile and lipid peroxidation were also evalu-
ated.
Materials and methods
Subjects
The protocol used was approved by the Committee on
Ethics of the University Hospital of Coimbra (Portu-
gal), and all the patients and controls gave their
consent. The control group included 40 apparently
healthy adults [55% men and 45% women,
mean ± SD age 47Æ4 ± 13Æ3 years, with a mean ± SD
body mass index (BMI) of 24Æ4 ± 1Æ8 kg m)2], with
no history of any skin disease, and presenting with
normal haematological and biochemical values. Alco-
holics were excluded from the study, as well as
individuals presenting with other associated diseases,
namely anaemia, diabetes mellitus, cardiovascular,
liver or kidney diseases.
The patient group comprised 70 adults (57% men and
43% women, mean ± SD age 45Æ9 ± 12Æ2 years and
BMI 24Æ6 ± 2Æ9 kg m)2) with mild or severe psoriasis
vulgaris. The disease was diagnosed from 0Æ5 to
50 years before this study. Disease severity was graded
according to the Psoriasis Area and Severity Index
(PASI) at the time of blood collection.22 About half of the
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patients had severe psoriasis or active psoriasis (AP)
(PASI > 3), and the other half of the patients had mild
psoriasis or inactive psoriasis (IP) (PASI < 3).
None of the patients had received any systemic or
local steroid medication or any phototherapy treatment
for at least 1 month prior to blood collection. In
addition, the controls, as well as the patients, were not
receiving any kind of medication, namely antioxidants,
vitamins or methotrexate. Moreover, we evaluated in
controls and patients the serum levels of vitamin B12,
folic acid and iron, and excluded all individuals
showing reduced values.
Collection and preparation of blood samples
Following fasting of the subjects for 12 h, blood was
collected with and without anticoagulant [ethylenedi-
amine tetraacetic acid (EDTA) and heparin as antico-
agulants], in order to obtain whole blood, plasma and
serum. None of the collected samples was icteric or
haemolysed.
To isolate RBCs and prepare their membranes,23–25
whole blood (EDTA as anticoagulant) was centrifuged
at 2300 g for 10 min at 4 C. The plasma was
processed for biochemical studies, the buffy coat was
discarded and the isolated RBCs were washed three
times in saline; afterwards, they were lysed by using a
hypotonic solution (Tris–HCl 1 mmol L)1, K2 EDTA
1Æ44 mmol L)1, pH 7Æ4). After 15 min under moderate
agitation, the haemolysates were centrifuged at
20 000 g for 10 min at 4 C. The RBC membrane
pellet obtained was carefully washed with aisotonic
buffer (Tris–HCl 1 mmol L)1, K2 EDTA 1Æ44 mmol L
)1,
NaCl 17 mmol L)1, pH 7Æ4) until almost complete
removal of Hb. The last wash was performed by using
a buffer solution of Tris–HCl 10 mmol L)1, pH 7Æ4. The
RBC membranes were resuspended in this buffer solu-
tion, immediately and rapidly frozen by submerging the
tubes with the membrane suspensions in liquid nitro-
gen, and stored at )80 C until assayed. These RBC
membrane suspensions were used for all membrane
study estimations except for the band 3 profile and the
MBH. For these, plasma and leucocytes were separated
from RBCs after centrifugation on a double density
gradient (Histopaque 1Æ077 and 1Æ119; Sigma, St Louis,
MO, U.S.A.). The RBCs were washed with saline and
immediately lysed, according to the method of Dodge
et al.26 The membranes were washed in Dodge buffer
(the first two washes used a protease inhibitor, phenyl-
methylsulphonyl fluoride, at a final concentration of
0Æ1 mmol L)1 in Dodge buffer) and frozen at )80 C
until assayed. The protein concentration of the mem-
brane suspensions was determined.27
Qualitative and quantitative red blood cell studies
Whole blood (EDTA as anticoagulant) was used for
haematological procedures. RBC and WBC count, Ht,
Hb concentration and the haematimetric indices [mean
cell volume (MCV), mean cell Hb (MCH) and mean cell
Hb concentration (MCHC)] were measured using an
automatic blood cell counter (Autocounter AC 970).
To evaluate the concentration of reticulocytes, a few
drops of the blood sample were taken and added to an
equal volume of brilliant cresyl blue solution (1% in
saline). After incubation at room temperature
(10 min), the percentage of reticulocytes was evaluated
in a blood smear and the respective concentration
calculated.
Erythrocyte osmotic fragility
The osmotic fragility test was performed according to a
previously described method.28 Briefly, saline solutions
buffered to pH 7Æ4 were used at different concentra-
tions (1Æ0–9Æ0 g L)1); heparinized blood was added to
these solutions in the proportion 1 : 100 (50 lL blood
in 5 mL of buffered solution); haemolysis was evalu-
ated after 30 min of incubation at room temperature
by measuring the absorbance at 540 nm of the
supernatant obtained after centrifugation (1500 g for
5 min). The absorbance of the isotonic RBC suspension
was used as the zero haemolysis, and the absorbance of
the most hypotonic solution as the total haemolysis.
The results were expressed as the concentration of the
hypotonic buffered saline in which we observed 50%
haemolysis.
Erythrocyte antioxidant defences
Heparinized blood was used to obtain the RBCs for the
evaluation of the enzymatic activities of Cat, SOD and
GPx, and the levels of GSH and Se. In the case of GPx,
the study was performed in whole blood, as its
plasmatic activity is extremely low when compared
with the RBC activity.29
Whole blood was centrifuged, the buffy coat was
discarded, and the isolated RBCs were washed in saline.
The RBC pellet was then used to evaluate Cat and SOD
activity. The activities of SOD and GPx were evaluated
by using commercially available kits (RANSOD and
RANSEL, respectively, from Randox, Crumlin, U.K.).
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The enzymatic activity of Cat was evaluated by using a
spectrophotometric method.30 All the spectrophoto-
metric analyses used an automatic analyser Hitachi
704 (Boehringer Mannheim, Mannheim, Germany).
The enzymatic activities were expressed as IU g)1 Hb.
The erythrocyte GSH levels (lmol g)1 Hb) were eval-
uated according to the method of Beutler et al.31
Hydride generation followed by atomic absorption
spectroscopy was used to determine the concentrations
of Se in whole blood and plasma, following digestion of
the samples with nitric and sulphuric acids.32 We then
estimated the RBC Se concentration by calculating the
difference between the whole blood and plasma values
obtained (data not shown).
Erythrocyte membrane studies
Erythrocyte membrane lipid peroxidation and membrane
susceptibility to lipid peroxidation Membrane lipid per-
oxidation was estimated by thiobarbituric acid (TBA)
reactivity (TBA assay).33 To evaluate the RBC mem-
brane susceptibility to lipid peroxidation, we evaluated
the TBA reactive species of the membranes, after an
in vitro stress imposed on RBCs by hydrogen peroxide
(2 h at 37 C).34 This RBC membrane susceptibility to
lipid peroxidation was also evaluated by the parinaric
acid (PnA) assay.35 Briefly, the oxidation of
1Æ5 lmol L)1 PnA incorporated in RBC ghosts
(200 lmol L)1 in Phlip) suspended in 10 mmol L)1
Tris-maleate, 150 mmol L)1 NaCl, pH 7Æ4, was
induced by free radicals generated with the Fe2+ ⁄ ascor-
bate system (1 lmol L)1 ⁄ 2 lmol L)1), at 37 C. The
incorporation of the fluorescent probe PnA was
achieved by incubating an aliquot of an ethanolic
solution (2 mmol L)1 PnA) with RBC ghosts for 2 min
before starting the oxidation reactions. The degrada-
tion was monitored by detecting the decay of fluores-
cence in a Perkin-Elmer LS-50 spectrofluorometer
(Norwalk, U.S.A.) with the excitation wavelength at
342 nm and the emission at 413 nm. The excitation
and emission slit widths were 5 and 5Æ5 nm, respect-
ively.36 Control experiments were performed to mon-
itor the spontaneous peroxidation of PnA in the
absence of the inducer system. The results are
expressed as the slope of fluorescence.
Erythrocyte membrane fluidity Erythrocyte membrane
fluidity was determined by using the hydrophobic
fluorescent probes 1,6-diphenyl-1,3,5-hexatriene
(DPH) and its cationic derivative 1-(4-trimethylamino-
phenyl)-6-phenyl-1,3,5-hexatriene (TMA-DPH) (Mole-
cular Probes, Junction City, OR, U.S.A.).
To perform the fluorescence polarization measure-
ments,37,38 the RBC membranes were dispersed in
50 mmol L)1 KCl, 10 mmol L)1 Tris-maleate, pH 7Æ0.
TMA-DPH and DPH, from a 2-mmol L)1 stock solution
in tetrafuran, were incorporated into membrane sus-
pensions (345 lmol L)1 in Phlip), in order to obtain a
lipid ⁄ probe molar ratio of about 400. The prepared
suspensions were incubated at 37 C for 2 h. The
fluorometric measurements were carried out with a
Perkin-Elmer LS-50 computer-controlled spectrofluoro-
meter. In the studies with both probes, the degree of
fluorescence polarization was determined as reported
elsewhere,39 excepting that the excitation and emission
slits were 3 and 4 nm, respectively. Appropriate control
experiments were carried out without added probes to
correct for the contribution of light scattering.
Erythrocyte membrane phospholipids and cholesterol As
an indirect marker of RBC membrane fluidity we
evaluated the levels of membrane Chol and Phlip, as
well as their ratio. Lipids were extracted from RBC
membranes by chloroform ⁄ methanol (2 : 1 v ⁄ v), fol-
lowed by chloroform ⁄ methanol ⁄ H2O (30 : 60 : 20
v ⁄ v ⁄ v), according to Alling et al.40 Chol content was
assayed enzymatically using Chol oxidase.41 Phlip
content was determined as inorganic phosphate by
the method of Bartlett,42 after hydrolysis at 180 C in
perchloric acid 70% (v ⁄ v).43
Erythrocyte membrane antioxidant defences Erythro-
cyte membrane vitamin E was evaluated by high-
performance liquid chromatography. Washed RBCs
(500 lL) were mixed with sodium dodecyl sulphate
(SDS; 1Æ5 mL, 10 mmol L)1), 2 mL of ethanol and
2 mL of n-hexane. We then used a vortex-type mixer to
extract vitamin E, by mixing for about 5 min. After
centrifugation at 3200 g for 5 min, we used 1 mL of the
organic phase, which was evaporated to dryness under a
gentle stream of nitrogen. These dry extracts, frozen at
)80 C until assayed, were dissolved in 250 lL of an
a-tocopherol solution (100 lg dL)1 in n-hexane).
The extracts were chromatographed in n-hex-
ane ⁄ methanol (99Æ1 : 0Æ9 v ⁄ v) at a flow rate of
1Æ5 mL min)1, by using a reversed-phase column
(Spherisorb S10W 250 · 4Æ6 mm) with ultraviolet
detection at 287 nm (HP 1100; Bio-Rad, Hercules,
CA, U.S.A.). The subsequent quantitative determin-
ation was then performed with the help of an
internal standard and the results expressed as
nmol g)1 Hb.
Membrane-bound haemoglobin MBH was measured
spectrophotometrically, after membrane protein disso-
ciation with Triton X-100 (5% in Dodge buffer); the
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absorbance was measured at 415 nm, and this value
was corrected by the background absorbance at
700 nm; the value obtained and the protein concen-
tration were used to estimate percentage MBH.
Erythrocyte membrane band 3 profile RBC membrane
suspensions were treated with an equal volume of a
solubilization buffer containing 0Æ125 mol L)1 Tris–
HCl pH 6Æ8, 4% SDS, 20% glycerol and 10% 2-
mercaptoethanol, heat denatured and submitted to
SDS–polyacrylamide gel electrophoresis (20 lg protein
per lane), using the discontinuous Laemmli system (a
9% separating gel and a 4Æ5% stacking gel).44 Mem-
brane proteins were electrophoretically transferred
from SDS gels to a nitrocellulose sheet with a porosity
of 0Æ2 lm (Sigma).45 Additional reactive sites on the
nitrocellulose were blocked by incubation in 3%
gelatine and 0Æ1% Triton-X 100 in phosphate-buffered
saline (PBS) pH 7Æ0 for 1 h at room temperature and
under gentle rotation. Band 3 immunoblot was per-
formed:46 antihuman band 3 monoclonal antibodies,
produced in mouse, recognizing an epitope located in
the cytoplasmic pole of the band 3 molecule47 (Sigma)
were added (dilution 1 : 3000) and incubated for 4 h;
washing of the nitrocellulose was followed by addition
and incubation with peroxidase-linked antimouse IgG
(Vector Laboratories, Burlingame, CA, U.S.A.) for 1 h
(dilution 1 : 4000). The incubations were carried out
at room temperature; the antibody dilutions were
prepared with PBS pH 7Æ0 containing 0Æ1% Triton-X
100 and 0Æ5% gelatine. In the washes, the same buffer
without gelatine was used. Hydrogen peroxide and
horseradish peroxidase colour developer reagent were
used to develop the immunoblot. The band 3 profile
was quantified by densitometry (Cybertech CS1); we
measured the percentage of each band, i.e. the
percentages of high molecular weight aggregates
(HMWAg), band 3 monomer and proteolytic fragments
(Pfrag).
Further assays
Leucocyte activation products Plasma concentration of
polymorphonuclear elastase and lactoferrin were evalu-
ated by enzyme immunoassays (PMN Elastase immuno-
assay, Merck, Darmstadt, Germany and Bioxytech
Lactof enzyme immunoassay, Oxis International, Port-
land, OR, U.S.A., respectively).
Oxidative stress Total plasma antioxidant capacity
was evaluated by a colorimetric assay (TAS, Randox).
Plasma lipid peroxidation was estimated by TBA
assay.33
Serum bilirubin Total serum bilirubin concentration
was evaluated by using a commercially available kit
(BIL-T; Roche, Basel, Switzerland).
Lipid profile Serum was used to study the lipid profile,
which included the evaluation of total Chol, triglycer-
ides (TG), high-density lipoprotein Chol (HDLc),
low-density lipoprotein Chol (LDLc), very low-density
lipoprotein Chol (VLDLc) and Phlip. Total Chol, TG and
Phlip concentrations were measured enzymatically by
using commercially available kits (Roche) on an
autoanalyser (Hitachi 704). HDLc was evaluated by
using the method described for total Chol, after
precipitation of the lipoproteins containing apolipopro-
tein B [LDL, VLDL and lipoprotein (a)] by a phospho-
tungstic acid ⁄ magnesium chloride mixture. LDLc was
computed by Friedwald’s equation.48
Statistical analysis
The statistical analysis was performed by using the
SPSS package. To evaluate differences between groups,
we used Student’s t-test for the determinations
presenting a Gaussian distribution, and the Mann–
Whitney test for those presenting a non-Gaussian
distribution. P < 0Æ05 was considered statistically
significant. The measurements are expressed as
mean ± SD. The strength of the association between
the parameters was estimated by the Pearson correla-
tion coefficient.
Results
All the results were analysed in two ways, on the one
hand to study the differences between healthy controls
and psoriasis patients, and on the other to evaluate the
changes according to the activity of the disease (mild
vs. severe psoriasis).
Qualitative and quantitative RBC studies (controls
and psoriasis patients) are presented in Table 1, as are
percentage and total reticulocytes, as markers of bone
marrow production, and the plasma levels of total
bilirubin, as a marker of RBC removal and destruction.
When compared with the control we found that total
psoriasis patients (IP + AP) had significantly lower
values for RBCs (P < 0Æ001), Ht (P < 0Æ001) and Hb
(P < 0Æ001). The haematimetric indices showed that
the RBCs from psoriasis patients were smaller
(P < 0Æ05) and with a reduced MCH (P < 0Æ01),
although the MCHC did not change. The percentage
and total reticulocytes were significantly higher in
patients (P < 0Æ001 and P < 0Æ05, respectively). The
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total bilirubin level was also significantly increased in
psoriasis patients (P < 0Æ01). The RBCs from patients
presented a significantly increased osmotic fragility
(P < 0Æ001).
When comparing the values for IP patients with
those for controls we found the same changes as for
total patients, with the exception of MCH and total
reticulocytes. In AP patients, we found the same
changes as for total patients. Most of the parameters
studied showed more pronounced changes in AP
patients than in IP patients, when compared with
controls. In severe psoriasis we found more reduced
values for RBCs, Ht, Hb, MCV and MCH, and more
increased values for reticulocytes (percentage and
total), bilirubin and osmotic fragility (Table 1).
When studying the values according to the severity
of psoriasis, i.e. comparing the values for IP patients
with those for AP patients (Table 1), we found that
most changes were enhanced significantly with wor-
sening of the disease.
The evaluation of total and differential WBC count
(Table 2) showed a significant rise in total WBC in
patients (P < 0Æ01), resulting from a significant
increase in neutrophils (P < 0Æ001) and lymphocytes
(P < 0Æ05); for monocytes we found a significant
reduction (P < 0Æ001). A significant reduction in the
RBC ⁄ neutrophil ratio was also observed (P < 0Æ001).
The rise in neutrophils seems to be associated with
their activation, as shown by the significant rise in
elastase (P < 0Æ001) and lactoferrin (P < 0Æ001).
When comparing patients with mild psoriasis with
controls (Table 2), we found that, despite a similar
value for total WBCs, there was a significant rise in
neutrophils (P < 0Æ001) and a significant reduction in
monocytes (P < 0Æ001), associated with significantly
higher values for elastase (P < 0Æ001) and lactoferrin
(P < 0Æ001).
In severe psoriasis, the rise in total WBCs
(P < 0Æ001) was significant when compared with
controls (Table 2), and this rise was linked to signifi-
cant rises in neutrophils (P < 0Æ001) and lymphocytes
(P < 0Æ001), as well as to significant rises in elastase
(P < 0Æ001) and lactoferrin (P < 0Æ001).
Concerning the severity of disease (IP vs. AP), we
found in severe psoriasis significantly higher values for
total and differential WBC count, associated with
significantly higher levels of leucocyte activation prod-
ucts (Table 2).
The evaluation of erythrocyte antioxidant defences
(Table 3) showed that psoriasis patients had a reduced
RBC antioxidant capacity, as shown by a significant
reduction in membrane vitamin E (P < 0Æ05),
GPx activity (P < 0Æ01), Se (P < 0Æ05) and GSH
(P < 0Æ001). No significant differences were found for
Cat and SOD. In mild psoriasis the same tendency was
observed, although significant differences were only
Table 1. Qualitative and quantitative red blood cell (RBC) study (mean ± SD) for controls and psoriasis patients
Controls
(n ¼ 40)
IP + AP
(n ¼ 70)
P-value
(IP + AP) ⁄
controls
IP
(n ¼ 40)
P-value
IP ⁄ controls
AP
(n ¼ 30)
P-value
AP ⁄ controls
P-value
IP ⁄ AP
Age (years) 47Æ4 ± 13Æ3 45Æ9 ± 12Æ2 NS 46Æ2 ± 13Æ0 NS 45Æ6 ± 11Æ4 NS NS
BMI (kg m)2) 24Æ4 ± 1Æ8 24Æ6 ± 2Æ9 NS 24Æ1 ± 3Æ2 NS 25Æ2 ± 2Æ5 NS NS
Smokers 17 (42Æ5%) 28 (40%) 15 (37Æ5%) 13 (43%)
RBCs
(· 1012 L)1)
4Æ91 ± 0Æ21 4Æ65 ± 0Æ19 < 0Æ001 4Æ70 ± 0Æ18 < 0Æ001 4Æ59 ± 0Æ19 < 0Æ001 < 0Æ05
Haematocrit
(L L)1)
0Æ46 ± 0Æ03 0Æ43 ± 0Æ02 < 0Æ001 0Æ44 ± 0Æ02 < 0Æ001 0Æ42 ± 0Æ02 < 0Æ001 < 0Æ01
Haemoglobin
(g dL)1)
14Æ6 ± 0Æ9 13Æ6 ± 0Æ7 < 0Æ001 13Æ8 ± 0Æ6 < 0Æ001 13Æ4 ± 0Æ7 < 0Æ001 < 0Æ01
MCV (fL) 94Æ4 ± 4Æ1 92Æ6 ± 2Æ2 < 0Æ05 92Æ8 ± 2Æ5 < 0Æ05 92Æ3 ± 1Æ9 < 0Æ01 NS
MCH (pg) 29Æ8 ± 0Æ7 29Æ3 ± 0Æ9 < 0Æ01 29Æ4 ± 0Æ9 NS 29Æ2 ± 0Æ9 < 0Æ01 NS
MCHC (g dL)1) 31Æ6 ± 1Æ4 31Æ7 ± 1Æ1 NS 31Æ7 ± 1Æ1 NS 31Æ6 ± 1Æ2 NS NS
OF (NaCl
solution: g L)1)
4Æ44 ± 0Æ04 4Æ48 ± 0Æ04 < 0Æ001 4Æ46 ± 0Æ03 < 0Æ01 4Æ50 ± 0Æ05 < 0Æ001 < 0Æ01
% Reticulocytes 1Æ19 ± 0Æ24 1Æ36 ± 0Æ16 < 0Æ001 1Æ30 ± 0Æ13 < 0Æ01 1Æ43 ± 0Æ16 < 0Æ001 < 0Æ001
Reticulocytes
(· 109 L)1)
58Æ0 ± 11Æ2 62Æ9 ± 7Æ5 < 0Æ05 61Æ2 ± 6Æ6 NS 65Æ2 ± 8Æ0 < 0Æ01 < 0Æ05
Bilirubin
(mg dL)1)
0Æ69 ± 0Æ12 0Æ76 ± 0Æ11 < 0Æ01 0Æ75 ± 0Æ10 < 0Æ05 0Æ76 ± 0Æ12 < 0Æ05 NS
IP, inactive psoriasis; AP, active psoriasis; BMI, body mass index; MCV, mean cell volume; MCH, mean cell haemoglobin; MCHC, mean cell
haemoglobin concentration; OF, osmotic fragility; NS, nonsignificant.
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found for GPx activity (P < 0Æ05) and for GSH
(P < 0Æ001). Patients with severe psoriasis presented
an enhancement in these changes. We observed a
significant reduction in membrane vitamin E
(P < 0Æ05), GPx activity (P < 0Æ01), Se (P < 0Æ05)
and GSH (P < 0Æ001).
Although a reduced RBC antioxidant capacity was
observed in AP patients, no significant differences were
observed with worsening of the disease (IP vs. AP).
A reduction in total plasma antioxidant capacity was
also observed in psoriasis patients (Table 3). We found
a significantly reduced value for TAS (P < 0Æ001) and
Table 2. Total and differential white blood cell (WBC) count and plasma neutrophil activation products, elastase and lactoferrin (mean ± SD), for
controls and psoriasis patients
Controls
(n ¼ 40)
IP + AP
(n ¼ 70)
P-value (IP + AP) ⁄
controls
IP
(n ¼ 40)
P-value IP ⁄
controls
AP
(n ¼ 30)
P-value AP ⁄
controls
P-value
IP ⁄ AP
WBCs
(· 109 L)1)
6Æ69 ± 1Æ30 7Æ59 ± 1Æ51 < 0Æ01 6Æ93 ± 1Æ28 NS 8Æ46 ± 1Æ37 < 0Æ001 < 0Æ001
Neutrophils
(· 109 L)1)
3Æ93 ± 0Æ77 5Æ15 ± 1Æ02 < 0Æ001 4Æ65 ± 0Æ81 < 0Æ001 5Æ81 ± 0Æ89 < 0Æ001 < 0Æ001
Lymphocytes
(· 109 L)1)
2Æ32 ± 0Æ45 2Æ53 ± 0Æ49 < 0Æ05 2Æ35 ± 0Æ43 NS 2Æ78 ± 0Æ47 < 0Æ001 < 0Æ001
Monocytes
(· 109 L)1)
0Æ24 ± 0Æ05 0Æ21 ± 0Æ05 < 0Æ001 0Æ19 ± 0Æ03 < 0Æ001 0Æ23 ± 0Æ05 NS < 0Æ001
RBC ⁄ neutrophils 1290 ± 238 933 ± 204 < 0Æ001 1033 ± 199 < 0Æ001 801 ± 118 < 0Æ001 < 0Æ001
(n ¼ 40) (n ¼ 60) (n ¼ 30) (n ¼ 30)
Age (years) 47Æ4 ± 13Æ3 46Æ1 ± 12Æ2 NS 46Æ6 ± 13Æ4 NS 45Æ6 ± 11Æ4 NS NS
BMI (kg m)2) 24Æ4 ± 1Æ8 24Æ7 ± 3Æ1 NS 24Æ2 ± 3Æ6 NS 25Æ2 ± 2Æ5 NS NS
Smokers 17 (42Æ5%) 25 (42%) 12 (40%) 13 (43%)
Lactoferrin
(lg L)1)
146Æ5 ± 54Æ3 241Æ0 ± 76Æ7 < 0Æ001 219Æ4 ± 68Æ1 < 0Æ001 262Æ6 ± 79Æ9 < 0Æ001 < 0Æ05
Elastase
(lg L)1)
54Æ8 ± 16Æ3 155Æ5 ± 69Æ7 < 0Æ001 105Æ2 ± 20Æ9 < 0Æ001 205Æ9 ± 64Æ9 < 0Æ001 < 0Æ001
AP, active psoriasis; IP, inactive psoriasis; BMI, body mass index; NS, nonsignificant.
Table 3. Erythrocyte antioxidant defences, plasma lipid peroxidation and antioxidant capacity (mean ± SD) for controls and psoriasis patients
Controls
(n ¼ 30)
IP + AP
(n ¼ 60)
P-value
(IP + AP) ⁄
controls
IP
(n ¼ 30)
P-value
IP ⁄ controls
AP
(n ¼ 30)
P-value
AP ⁄ controls
P-value
IP ⁄ AP
Age (years) 45Æ2 ± 14Æ6 45Æ6 ± 12Æ0 NS 45Æ7 ± 12Æ8 NS 45Æ6 ± 11Æ4 NS NS
BMI (kg m)2) 24Æ1 ± 1Æ8 24Æ8 ± 3Æ1 NS 24Æ4 ± 3Æ5 NS 25Æ2 ± 2Æ5 NS NS
Smokers 13 (43%) 25 (42%) 12 (40%) 13 (43%)
Vitamin E
(nmol g)1 Hb)
13Æ2 ± 3Æ1 11Æ9 ± 2Æ5 < 0Æ05 12Æ3 ± 2Æ6 NS 11Æ4 ± 2Æ4 < 0Æ05 NS
Catalase
(IU · 104 g)1 Hb)
5Æ77 ± 1Æ26 5Æ45 ± 1Æ22 NS 5Æ55 ± 1Æ29 NS 5Æ35 ± 1Æ16 NS NS
GPx
(IU g)1 Hb)
59Æ0 ± 11Æ6 50Æ9 ± 11Æ1 < 0Æ01 51Æ7 ± 10Æ1 < 0Æ05 50Æ1 ± 12Æ2 < 0Æ01 NS
SOD
(IU g)1 Hb)
1495 ± 222 1587 ± 249 NS 1561 ± 247 NS 1612 ± 252 NS NS
GSH
(lmol g)1 Hb)
11Æ75 ± 1Æ03 9Æ78 ± 1Æ09 < 0Æ001 9Æ89 ± 1Æ09 < 0Æ001 9Æ66 ± 1Æ09 < 0Æ001 NS
Se (lg L)1) 59Æ9 ± 15Æ2 52Æ9 ± 13Æ9 < 0Æ05 54Æ8 ± 12Æ9 NS 50Æ7 ± 15Æ0 < 0Æ05 NS
TAS
(mmol L)1)
1Æ63 ± 0Æ18 1Æ38 ± 0Æ25 < 0Æ001 1Æ51 ± 0Æ16 < 0Æ05 1Æ25 ± 0Æ25 < 0Æ001 < 0Æ001
TBA (· 10)3
mmol L)1)
2Æ13 ± 0Æ52 5Æ89 ± 1Æ30 < 0Æ001 5Æ06 ± 1Æ10 < 0Æ001 6Æ72 ± 0Æ89 < 0Æ001 < 0Æ001
TBA ⁄ TAS 1Æ32 ± 0Æ38 4Æ56 ± 1Æ85 < 0Æ001 3Æ40 ± 0Æ92 < 0Æ001 5Æ72 ± 1Æ82 < 0Æ001 < 0Æ001
IP, inactive psoriasis; AP, active psoriasis; BMI, body mass index; Hb, haemoglobin; GPx, glutathione peroxidase; SOD, superoxide dismutase; GSH,
reduced glutathione; Se, selenium; TAS, total plasma antioxidant capacity; TBA, thiobarbituric acid reactivity, a measure of plasma lipid per-
oxidation; NS, nonsignificant.
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higher values for TBA (P < 0Æ001) and for the ratio
TBA ⁄ TAS (P < 0Æ001). The same changes were
observed for mild psoriasis, when compared with
controls, and changes were further enhanced in severe
psoriasis. When comparing these values according to
the severity of the disease (IP vs. AP) we found
significant differences, denoting a linkage of severe
psoriasis with a reduction in the erythrocyte anti-
oxidant capacity and the development of oxidative
stress within the cell.
Table 4 shows the erythrocyte membrane damage
observed in controls and in psoriasis patients. When
compared with the control group, we found that total
psoriasis patients showed higher membrane lipid per-
oxidation and a higher susceptibility to membrane lipid
peroxidation (both with TBA and with PnA assay)
(P < 0Æ001). Moreover, we found in psoriasis patients a
significantly lower membrane fluidity, as shown by the
polarization probes DPH and TMA-DPH (P < 0Æ001) in
association with a higher Chol ⁄ Phlip ratio (P < 0Æ01).
MBH, a marker of oxidative stress in RBCs, also showed
a significantly higher value (P < 0Æ001). The band 3
profile presented a significantly different pattern for
psoriasis patients: the percentage of HMWAg was
almost double the control value and the band 3
monomer decreased (P < 0Æ001); no significant differ-
ence was found for Pfrag of band 3. The same
modifications were observed in IP and AP patients
when compared with controls, except for the band 3
profile of AP patients, in which the reduction in Pfrag
reached statistical significance. All these RBC
membrane modifications were enhanced in AP
patients, and when we compared IP vs. AP we found
significantly different values with the exception of
Chol ⁄ Phlip ratio and band 3 profile.
To provide further evidence of the involvement of
leucocytes with plasma and RBC damage, we looked for
significant correlations between them. We found a
positive correlation of both total WBC and neutrophils
with the levels of lipid peroxidation in plasma
(R ¼ 0Æ548, P < 0Æ001; R ¼ 0Æ455, P < 0Æ001,
respectively). A positive correlation was also found for
elastase with both total WBC and neutrophils
(R ¼ 0Æ617, P < 0Æ001; R ¼ 0Æ799, P < 0Æ001), and
for lactoferrin with neutrophil count (R ¼ 0Æ515,
P < 0Æ001). Stronger correlations were found in severe
psoriasis (R ¼ 0Æ589, P < 0Æ001; R ¼ 0Æ848,
P < 0Æ001; R ¼ 0Æ642, P < 0Æ001, respectively). The
levels of lipid peroxidation in the RBC membrane were
negatively correlated with the enzymatic activity of
GPx and Cat (R ¼ )0Æ506, P < 0Æ001; R ¼ )0Æ397,
P < 0Æ001, respectively), and these values were higher
for severe psoriasis (R ¼ )0Æ526, P < 0Æ001;
R ¼ )0Æ643, P < 0Æ001, respectively). We also
observed a positive correlation between the levels of
lipid peroxidation in plasma and in the RBC membrane
(R ¼ 0Æ591, P < 0Æ001). Again, a positive correlation
was observed between membrane lipid peroxidation
and the band 3 aggregation (R ¼ 0Æ525, P < 0Æ001).
Negative correlations were found in severe psoriasis
between the aggregation of band 3 and the activity of
Cat and GPx, and the GSH levels (R ¼ )0Æ467,
Table 4. Erythrocyte membrane damage (mean ± SD) for controls and psoriasis patients
Controls
(n ¼ 30)
IP + AP
(n ¼ 60)
P-value
(IP + AP) ⁄ controls
IP
(n ¼ 30)
P-value
IP ⁄ controls
AP
(n ¼ 30)
P-value
AP ⁄ controls
P-value
IP ⁄ AP
DPH 0Æ332 ± 0Æ006 0Æ358 ± 0Æ007 < 0Æ001 0Æ354 ± 0Æ004 < 0Æ001 0Æ362 ± 0Æ007 < 0Æ001 < 0Æ001
TMA-DPH 0Æ382 ± 0Æ006 0Æ412 ± 0Æ007 < 0Æ001 0Æ410 ± 0Æ006 < 0Æ001 0Æ414 ± 0Æ006 < 0Æ001 < 0Æ05
Chol ⁄ Phlip 0Æ748 ± 0Æ137 0Æ830 ± 0Æ104 < 0Æ01 0Æ809 ± 0Æ090 < 0Æ05 0Æ852 ± 0Æ114 < 0Æ01 NS
TBA (0 h) 0Æ162 ± 0Æ019 0Æ234 ± 0Æ066 < 0Æ001 0Æ209 ± 0Æ055 < 0Æ001 0Æ259 ± 0Æ067 < 0Æ001 < 0Æ01
TBA (2 h) 0Æ351 ± 0Æ037 0Æ488 ± 0Æ142 < 0Æ001 0Æ437 ± 0Æ132 < 0Æ01 0Æ539 ± 0Æ134 < 0Æ001 < 0Æ01
PnA ) 2Æ63 ± 1Æ01 ) 5Æ08 ± 1Æ70 < 0Æ001 ) 4Æ55 ± 1Æ41 < 0Æ001 ) 5Æ62 ± 1Æ82 < 0Æ001 < 0Æ05
(n ¼ 29) (n ¼ 34) (n ¼ 18) (n ¼ 17)
Band 3
HMWAg
(%)
9Æ7 ± 5Æ2 17Æ8 ± 4Æ8 < 0Æ001 16Æ7 ± 4Æ4 < 0Æ001 18Æ9 ± 5Æ0 < 0Æ001 NS
Band 3 (%) 63Æ5 ± 4Æ2 56Æ7 ± 4Æ8 < 0Æ001 56Æ2 ± 3Æ2 < 0Æ001 57Æ2 ± 6Æ0 < 0Æ001 NS
Pfrag (%) 26Æ8 ± 4Æ5 25Æ5 ± 5Æ9 NS 27Æ2 ± 6Æ6 NS 23Æ9 ± 4Æ6 < 0Æ05 NS
MBH
(· 10)4%)
96 ± 32 257 ± 134 < 0Æ001 202 ± 109 < 0Æ01 312 ± 137 < 0Æ001 < 0Æ05
IP, inactive psoriasis; AP, active psoriasis; DPH, 1,6-diphenyl-1,3,5-hexatriene; TMA-DPH, 1-(4-trimethylaminophenyl)-6-phenyl-1,3,5-hexatri-
ene (values show fluorescence of polarization); Chol, cholesterol; Phlip, phospholipids; TBA, thiobarbituric acid (lmol g)1 haemoglobin); PnA,
parinaric acid (slope value); HMWAg, high molecular weight aggregates; Pfrag, proteolytic fragments; MBH, membrane-bound haemoglobin; NS,
nonsignificant.
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P < 0Æ001; R ¼ )0Æ501, P < 0Æ001; R ¼ )0Æ558,
P < 0Æ001, respectively).
Table 5 shows the lipid profile presented by controls
and psoriasis patients. When compared with controls,
we found that total psoriasis patients presented
significantly higher values for Chol (P < 0Æ01), TG
(P < 0Æ01), LDLc (P < 0Æ01), VLDLc (P < 0Æ01) and
Chol ⁄ Phlip ratio (P < 0Æ05); significantly lower values
were found for HDLc (P < 0Æ001). Patients with mild
psoriasis presented only a significant reduction in
HDLc (P < 0Æ01), while AP patients presented the
same significant changes as for total patients. When
comparing IP vs. AP patients a significant rise was
found for Chol (P < 0Æ05), TG (P < 0Æ01) and VLDLc
(P < 0Æ01).
Discussion
Psoriasis as a clinically inflammatory skin disease
seems to impose an oxidative stress condition.1,2 The
activation of the inflammatory cells in psoriasis may
result in increased leucocyte activation products in the
peripheral blood,3,4 which may induce oxidative
and proteolytic modifications to plasma constituents
and neighbouring cells such as circulating erythro-
cytes.10–12 Considering that the RBC has a very limited
biosynthesis capacity, physical and ⁄ or chemical dam-
age will accumulate throughout its life span. Therefore,
we considered it reasonable that the erythrocyte
could provide a cumulative marker of oxidative and
proteolytic stress in psoriasis, and also a marker of
worsening of the disease. In this perspective, we studied
the erythrocyte in psoriasis patients, half with mild
psoriasis and the other half with severe psoriasis. The
RBC was evaluated in different ways, by searching for
oxidative and ⁄ or proteolytic damage, and by searching
for a correlation with leucocyte activation and oxida-
tive stress development.
We found that psoriasis patients presented a higher
number of WBCs (Table 2) and that this rise was
mainly due to an increased number of neutrophils. The
higher plasma levels of neutrophil activation prod-
ucts—elastase and lactoferrin—in psoriasis patients
may reflect the higher number of neutrophils and ⁄ or
higher neutrophil activation. It is known that neutro-
phil activation is also linked to the production of
oxygen metabolites, which may trigger oxidative mod-
ifications in plasma constituents and in cell mem-
branes.5–12 The evaluation of plasma levels of lipid
peroxidation (Table 3) showed a significantly higher
value in psoriasis, along with a significantly reduced
total plasma antioxidant capacity. The TBA ⁄ TAS ratio
clearly reveals the development of an oxidative stress
condition in psoriasis.
Some oxygen metabolites are highly reactive,
whereas others, such as hydrogen peroxide, are less
reactive and have the ability to diffuse easily across the
cell membranes, namely the erythrocyte membranes.
They may therefore impose oxidative modifications
upon the membrane and within the RBC. Gaining the
Table 5. Lipid profile (mean ± SD) for controls and psoriasis patients
Controls
(n ¼ 40)
IP + AP
(n ¼ 60)
P-value
(IP + AP) ⁄ controls
IP
(n ¼ 30)
P-value
IP ⁄ controls
AP
(n ¼ 30)
P-value
AP ⁄ controls
P-value
IP ⁄ AP
Age (years) 47Æ4 ± 13Æ3 45Æ4 ± 11Æ6 NS 45Æ1 ± 12Æ0 NS 45Æ6 ± 11Æ4 NS NS
BMI
(kg m)2)
24Æ4 ± 1Æ8 24Æ9 ± 3Æ0 NS 24Æ5 ± 3Æ4 NS 25Æ2 ± 2Æ5 NS NS
Smokers 17 (42Æ5%) 24 (40%) 11 (37%) 13 (43%)
Chol
(mg dL)1)
199Æ8 ± 27Æ7 219Æ6 ± 39Æ4 < 0Æ01 207Æ7 ± 41Æ7 NS 231Æ4 ± 33Æ7 < 0Æ001 < 0Æ05
TG
(mg dL)1)
92Æ6 ± 27Æ3 119Æ6 ± 54Æ2 < 0Æ01 99Æ2 ± 52Æ4 NS 140Æ0 ± 48Æ7 < 0Æ001 < 0Æ01
HDLc
(mg dL)1)
50Æ0 ± 3Æ2 44Æ7 ± 5Æ7 < 0Æ001 45Æ9 ± 5Æ7 < 0Æ01 43Æ5 ± 5Æ5 < 0Æ001 NS
LDLc
(mg dL)1)
131Æ3 ± 27Æ9 151Æ0 ± 37Æ6 < 0Æ01 142Æ0 ± 39Æ9 NS 159Æ9 ± 33Æ4 < 0Æ001 NS
VLDLc
(mg dL)1)
18Æ6 ± 6Æ3 24Æ3 ± 10Æ7 < 0Æ01 20Æ5 ± 10Æ5 NS 28Æ0 ± 9Æ7 < 0Æ001 < 0Æ01
Phlip
(mg dL)1)
200Æ9 ± 28Æ1 200Æ4 ± 32Æ6 NS 196Æ9 ± 28Æ6 NS 203Æ9 ± 36Æ2 NS NS
Chol ⁄ Phlip 1Æ01 ± 0Æ19 1Æ12 ± 0Æ25 < 0Æ05 1Æ07 ± 0Æ22 NS 1Æ17 ± 0Æ26 < 0Æ01 NS
IP, inactive prosiasis; AP, active psoriasis; BMI, body mass index; Chol, cholesterol; TG, triglycerides; HDLc, high-density lipoprotein cholesterol;
LDLc, low-density lipoprotein cholesterol; VLDLc, very low-density lipoprotein cholesterol; Phlip, phospholipids, NS, nonsignificant.
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inside of the RBC, they will trigger the erythrocyte
antioxidant defence mechanisms. When these RBC
defences are depleted, an oxidative stress will develop
within the cell and therefore oxidative modifications
will appear. In psoriasis patients we observed a
reduction in the erythrocyte antioxidant defences. We
found reduced levels of GSH and Se, and reduced
enzymatic activity for Cat and GPx (Table 3). These
enzymes are particularly involved in the detoxification
of the cell in oxygen radicals and it seems that the
failure of this mechanism may account for the lipid
peroxidation of the RBC membrane, as suggested by the
significant negative correlations of Cat and GPx activity
with RBC membrane lipid peroxidation. Moreover, the
RBC membrane levels of the antioxidant vitamin E
were also reduced in psoriasis patients.
Together, the above results suggest the development
of oxidative stress within the RBC, with failure of
membrane and cytoplasmic antioxidant defences
(Table 3). Strengthening these observations, we found
(Table 4) that the RBC membrane lipid peroxidation
and the membrane susceptibility to lipid peroxidation
were higher in psoriasis patients, as shown by the
higher levels of TBA in RBC membranes, before and
after 2 h of in vitro imposed oxidative stress. The higher
value of membrane lipid peroxidation in patients was
corroborated by using the PnA assay. These results,
and those reflecting a depletion in membrane and
cytoplasmic antioxidant defences, are mostly in
agreement with previous observations of other
authors.20,21,49–51 In the case of SOD, some authors
reported a reduced activity in psoriasis patients, while
others, including ourselves, found an increase.
In searching for oxidative modifications which would
result from the developed oxidative stress, the evalua-
tion of MBH, denoting the oxidation of Hb, showed a
sharp rise in psoriasis patients. It is known that
the linkage of denatured Hb to the RBC membrane at
the cytoplasmic pole of the protein band 3 favours the
aggregation of this transmembrane protein.18 In
accordance with this, we found a different band 3
profile in psoriasis patients, which showed a significant
rise in HMWAg of band 3 (Table 4). The development
and accumulation of the several oxidative modifica-
tions in the RBC must lead to changes in the osmotic
fragility of the cell and in the membrane fluidity. We
found an increased osmotic fragility (Table 1) and a
reduced fluidity in the erythrocytes from psoriasis
patients (Table 4). We observed an increased mem-
brane fluorescence polarization, when using DPH and
TMA-DPH as probes, and a rise in the Chol ⁄ Phlip ratio,
both reflecting a reduction in membrane fluidity. The
higher RBC membrane Chol ⁄ Phlip ratio in psoriasis
patients was linked to a higher serum Chol ⁄ Phlip ratio
(Table 5). Thus, the observed changes in membrane
fluidity may reflect the dyslipidaemia and the enhanced
production of ROS, which increases lipid peroxidation
and induces depletion of the antioxidant defences.
Psoriasis has been associated with oxidative stress,
abnormal plasma lipid metabolism and a high fre-
quency of cardiovascular events.1,52 The changes we
observed in the lipid profile of psoriasis patients were all
risk changes and seemed to be enhanced in severe
psoriasis.
Reductions in total RBC count, MCV and enzymatic
activity with failure of the cytoplasmic and membrane
antioxidant defences, and a rise in the osmotic fragility,
are all marks of RBC senescence or damage, and these
changes were observed in psoriasis patients (Table 1).
Plasma levels of total bilirubin were higher in psoriasis
patients, denoting an enhanced RBC damaging and ⁄ or
ageing process and the consequent enhancement in
RBC removal. Strengthening this hypothesis, and
expressing the physiological mechanism to counterbal-
ance a higher RBC removal, we found a higher number
of reticulocytes in psoriasis patients.
It is known that the rise in the levels of some
cytokines along inflammatory processes may underlie a
reduction in erythropoietin production, in iron release
from reticuloendothelial stores, in the proliferation of
erythroid progenitors, and therefore in the number of
circulating RBCs.53 In the present study we found a
reduction in RBC count; however, it was accompanied
by changes denoting an enhancement in RBC damage,
followed by changes denoting a slightly enhanced RBC
removal and a slightly enhanced production of RBCs,
as shown by a higher reticulocyte count. Therefore,
considering that subjects with deficiencies in erythro-
poietic nutrients were excluded from the study, it seems
that the reduction in RBC count is mainly connected
with the development of oxidative stress and worsening
of psoriasis.
We looked for a correlation between total WBC and
neutrophil counts and plasma lipid peroxidation to
clarify the role played by those cells in this disease, and
found a significant positive correlation between them.
This suggests that the leucocyte rise is linked to cell
activation, as the activated neutrophils are important
sources of oxygen metabolites, which probably account-
ed for the rise in plasma lipid peroxidation. We also
found a positive correlation between neutrophil count
and the plasma levels of the neutrophil activation
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products elastase and lactoferrin, reflecting the rise
and ⁄ or activation of neutrophils.
The comparison of mild (IP) and severe (AP) psoriasis
with the controls showed that most of the changes seen
in psoriasis patients (IP + AP) were already observed in
mild psoriasis, with the exception of MCH, total
reticulocytes, WBCs and lymphocytes, RBC membrane
vitamin E and selenium. In severe psoriasis all the
changes became significantly different from the con-
trols, suggesting that the worsening of the disease is
associated with the enhancement of neutrophil activa-
tion, and therefore with an even more accelerated RBC
damage and ⁄ or ageing process and a higher RBC
removal and reticulocyte release.
Our study focused on the erythrocyte as a marker for
the worsening of psoriasis, which suddenly and unex-
pectedly develops from mild to severe with enlargement
of the psoriasis lesions. Therefore, looking for an early
predictive index for the development of a psoriasis
crisis, we compared the values obtained in mild and
severe psoriasis. We found that the enlargement of
psoriasis lesions was associated with a reduction in
RBCs, a rise in reticulocytes, and the development of
erythrocyte changes denoting enhanced damage,
namely a rise in osmotic fragility, in membrane lipid
peroxidation and in its susceptibility to lipid peroxida-
tion, and in MBH, showing a failure in the cytoplasmic
antioxidant defences. The worsening of the disease was
also associated with a reduction in RBC membrane
fluidity. Considering that, as suggested by the present
study, erythrocyte damage is enhanced in psoriasis,
particularly in severe psoriasis, these patients are more
prone to develop anaemia. This is probably of partic-
ular value for those patients with severe psoriasis,
presenting excessive losses of iron in scales, and in
those who, being resistant to conventional therapeutic
agents, are under methotrexate therapy.54
Neutrophil count and its activation products elastase
and lactoferrin, as well as the oxidative damage of the
RBC membrane, may provide predictive markers for
worsening of psoriasis. Values for elastase and MBH
were almost double in severe psoriasis. Therefore, we
suggest that a regular evaluation of these potential
markers in patients with mild psoriasis could be of
value in predicting in advance the worsening of the
disease and therefore enabling earlier therapeutic
intervention. Moreover, our data clearly suggest the
need for a therapeutic study on the value of inhibiting
the neutrophil activation process and its deleterious
effects upon neighbouring cells.
In a previous study,1 we found that psoriasis patients
presented a different lipid profile, with several modifi-
cations of risk for cardiovascular events, and that these
changes were enhanced with worsening of the disease.
The activation of leucocytes resulting in increased
levels of leucocyte activation products in the peripheral
blood of psoriasis patients may favour atherogenesis by
promoting the oxidation of LDL. Moreover, these
activation products seem to contribute to a higher
erythrocyte membrane rigidity by imposing oxidative
modifications to RBCs. The rise in circulating WBCs,
with a reduced capacity to deform, and the rise in RBCs
with a reduced membrane elasticity, may enhance the
inflammatory and the RBC damage process, by increas-
ing the blood viscosity and reducing the blood flow at
the psoriasis lesions. In addition, we wonder if the
increased blood viscosity, resulting from the association
of leucocyte activation and RBC damage with dyslipid-
aemia and a reduced antioxidant capacity in psoriasis,
could not explain in part the higher prevalence of
cardiovascular events in these patients.
In summary, our data show a reduced number of
erythrocytes in psoriasis patients, and present several
changes denoting an enhanced damage and ⁄ or ageing
process, which seem to be strongly connected with
neutrophil activation, oxidative stress and worsening of
psoriasis.
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